We would love to hear your thoughts about our site and services, please take our survey here.
Sorry 251 to 259 in the blink of an eye
I got in too. Quoted 151, refreshed the screen and it was 259. That’s what I paid so I’m keeping everything crossed now.
This is the part the May catch people’s eyes imo ‘ Primarily for reasons of the ASP, the total potential revenue of the five OEM cells in Knowsley is likely to be circa GBP75m per annum and not the previously stated GBP50m with no change to the anticipated cost of building each cell’.
I was thinking the same thing. You know how the market is. Unless the rns has numbers in it, it probably won’t much difference to the share price.
The TU might so bring it on.
Wed, 21st Oct 2020 07:00
RNS Number : 7026C
Yourgene Health PLC
21 October 2020
Yourgene Health plc
("Yourgene Health" or the "Company")
Yourgene Genomic Services collaboration with Cytox
Partnership with Cytox to enable clinical access to genoSCORE™ - a new genetic test to determine the risk of developing Alzheimer's disease
Manchester, UK - 21 October 2020: Yourgene Health (AIM: YGEN), a leading international molecular diagnostics group, announces a new collaboration between the recently launched Yourgene Genomic Services ("YGS") and Cytox Ltd ("Cytox"), for a beta-testing genomic study on their genetic risk test for Alzheimer's disease ("AD").
Under the YGS offering, Yourgene Health will validate and verify the performance of the Cytox genoSCORE-LAB1 process for both whole blood and saliva samples, to ensure the robust and reproducible detection of genotypes necessary to calculate individual polygenic risk scoring ("PRS").
YGS was launched recently to bring together a number of Yourgene's core capabilities, creating a service business that supports partners at the preclinical, clinical and post-market stages as they develop, manufacture, obtain regulatory approval and commercialise new products and services. Cytox specialises in developing and commercialising PRS algorithms to characterise an individual's genetic risk for developing AD. Both parties are exploring a potential partnership to provide genoSCORE as a clinical testing service from Yourgene's UK laboratory in Manchester next year once Cytox have formally launched the test.
Lyn Rees, CEO of Yourgene Health plc, commented: "This is an exciting partnership for Yourgene Genomic Services and a fine example of our ever-increasing product and service offering. We already have a well-established relationship with Cytox and are looking forward to working with them on this progressive technology. I look forward to updating shareholders in the near future."
Dr. Richard Pither, CEO of Cytox, commented: "In Europe there are an estimated 1.6 million new cases of dementia each year, of which 800,000 are Alzheimer's disease. As part of the disease management pathway, we anticipate clinicians adopting genoSCORE-LAB not only as an early test for patients concerned about future AD risk, but also to provide additional insight into potential disease progression in existing patients. We look forward to working with the Yourgene team on this initial Beta testing study ahead of our product launch."
1genoSCORE™-LAB - genetic test to predict future risk of developing AD. The test, which uses a simple blood or saliva sample, analyses patient genotypes against an array of about 114,000 single nucleotide polymorphisms (SNPs) that have been associated with AD. As such, the test generates a patient-specific PRS.